Aradigm Corporation, which filed for bankruptcy in February 2019, said that it will sell all of its assets related to Lipoquin inhaled ciprofloxacin, Apulmiq (Linhaliq) dual release inhaled ciprofloxacin, and other inhaled ciprofloxacin candidates to Grifols, subject to approval by the bankruptcy court. The deal also leaves Aradigm “free to accept higher and better bids at auction,” the company said.
In 2013, Grifols acquired an exclusive license to Aradigm’s inhaled ciprofloxacin formulations. The new deal includes all intellectual property and patents related to those programs. According to the terms of the deal, Grifols will pay ~$3.25 million in cash and will waive claims totaling more than $30 million in the bankruptcy case. In addition, Grifols will make milestone payments to Aradigm if any of the products is approved by the FDA or EMA, as well as paying 25% of any royalties received.
In January 2018, Aradigm received a CRL in response to its NDA for Apulmiq for the treatment of P. aeruginosa infections in NCFBE patients. A year later, Aradigm said that the FDA had indicated that it still had concerns regarding data from Phase 3 trials of Apulmiq. In the EU, the company withdrew its MAA for Linhaliq for the same indication in October 2019 after learning that it would be unlikely to receive a positive recommendation from CHMP.
Read the Aradigm press release.
